Posted by Michael Wonder on 19 Aug 2019
RFP - supply of infliximab
19 August 2019 - PHARMAC invites proposals for the supply of infliximab in New Zealand.
Remicade (supplied by Janssen New Zealand) has hospital sole supply status until 29 February 2020 as a result of the agreement reached with Janssen following a Request for Tenders issued in 2014. Note that a confidential rebate applies to all sales of Remicade to DHB Hospitals (including via Contract Manufacturers), which reduces the net cost of Remicade to DHBs.
PHARMAC is not aware of any New Zealand current patents in place relating to infliximab; however, PHARMAC makes no representation as to the patent status and descriptions outlined above and accepts no liability for any patent infringement that might occur as a result of this RFP process or PHARMAC’s acceptance of any proposals.
